Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) has a cash flow conversion efficiency ratio of 0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-349.69K) by net assets ($-2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LABT stock market capitalisation for the company's overall valuation and market capitalisation.
Lakewood-Amedex Biotherapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Lakewood-Amedex Biotherapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lakewood-Amedex Biotherapeutics Inc. Com share price for real-time trading data and today's change.
Lakewood-Amedex Biotherapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lakewood-Amedex Biotherapeutics Inc. Common Stock ranked by their cash flow conversion efficiency. Review Lakewood-Amedex Biotherapeutics Inc. Com financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rights and Issues Investment Trust Public Limited Company
LSE:RIII
|
0.009x |
|
Nusantara Inti Corpora Tbk
JK:UNIT
|
-0.084x |
|
Wang & Lee Group, Inc. Ordinary Shares
NASDAQ:WLGS
|
0.051x |
|
Astron Paper & Board Mill Limited
NSE:ASTRON
|
0.079x |
|
Valora Effekten Handel AG
F:VEH
|
N/A |
|
elexxion AG
XETRA:E8X
|
-708202.000x |
|
TELES Informationstechnologien AG
XETRA:TLIK
|
N/A |
|
Advent Technologies Holdings Inc
NASDAQ:ADN
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Lakewood-Amedex Biotherapeutics Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2023 to 2025. Also see Lakewood-Amedex Biotherapeutics Inc. Com balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.96 Million | $-1.94 Million | 0.990x | +107.08% |
| 2024-12-31 | $409.61K | $-5.72 Million | -13.973x | -834.43% |
| 2023-12-31 | $4.56 Million | $-6.82 Million | -1.495x | -- |
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic f… Read more